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Abstract
Background—The role of estrogen and progesterone in the development of endometrial cancer
is well documented. Few studies have examined the association of genetic variants in sex
hormone-related genes with endometrial cancer risk.
Methods—We conducted a case-control study nested within three cohorts to examine the
association of endometrial cancer risk with polymorphisms in hormone-related genes among 391
cases (92% postmenopausal at diagnosis) and 712 individually-matched controls. We also
examined the association of these polymorphisms with circulating levels of sex hormones and
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SHBG in a cross-sectional analysis including 596 healthy postmenopausal women at blood
donation (controls from this nested case-control study and from a nested case-control study of
breast cancer in one of the three cohorts).
Results—Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was
significantly associated (ORper allele = 1.22, 95% CI = 1.01–1.47, ptrend = 0.04), while the T allele
of rs10046 was marginally associated with increased risk of endometrial cancer (ORper allele =
1.20, 95% CI = 0.99 – 1.45, ptrend = 0.06). PGR rs1042838 was also marginally associated with
risk (ORper allele = 1.25, 95% CI = 0.96–1.61, ptrend = 0.09). No significant association was found
for the other polymorphisms, i.e. CYP1B1 rs1800440 and rs1056836, UGT1A1 rs8175347, SHBG
rs6259 and ESR1 rs2234693. Rs8175347 was significantly associated with postmenopausal levels
of estradiol, free estradiol and estrone and rs6259 with SHBG and estradiol.
Conclusion—Our findings support an association between genetic variants in CYP19, and
possibly PGR, and risk of endometrial cancer.
Keywords
endometrial cancer; estrogen; sex hormone-binding globulin; progesterone receptor; single
nucleotide polymorphism
Introduction
The role of estrogens and progesterone in the development of endometrial cancer is well
documented [1]. The few prospective studies that have reported on the association between
endogenous sex hormones and endometrial cancer risk have shown that circulating levels of
androgens and estrogens in postmenopausal women are positively related to risk [2–4]. A
number of single-nucleotide polymorphisms (SNPs) and/or haplotypes in hormone-related
genes have also been studied, with mixed results [5, 6]. We conducted a case-control study
nested within three cohorts to examine the association of several SNPs and repeat
polymorphisms in sex hormone-related genes with endometrial cancer risk in predominantly
postmenopausal women.
Polymorphisms were studied from the following genes: CYP19, coding for aromatase which
converts androgens to estrogens; CYP1B1, coding for the cytochrome P450 1B1 which
hydroxylates estrogens to catecholestrogens; UGT1A1, coding for UDP-
glucuronosyltransferase 1A1 which glucuronidates estrogens; SHBG, coding for sex
hormone-binding globulin (SHBG) which binds estrogens and androgens, reducing their
biological availability; and ESR1, coding for the estrogen receptor alpha. Specific
polymorphisms (with minor allele frequencies >10%) were selected based on their potential
functional impact [e.g. association with endogenous hormone or SHBG levels [7–13] or
possible role in regulation of gene transcript expression involved in hormone signaling [14,
15]] and because at least one prior study had reported an association with endometrial
cancer risk [7, 16–21] at the time of initiation of this study. The polymorphisms chosen
were: CYP19, rs4775936 and rs10046 [7–9]; CYP1B1, rs1800440 and rs1056836 [20, 22];
UGT1A1, rs8175347 [17, 23]; SHBG, rs6259 [9, 18, 24]; PGR, rs1042838 [16, 25–27]; and
ESR1, rs2234693 [21, 28, 29]. Because of budget limitations, we examined only a limited
number of polymorphisms. We selected genetic variants for inclusion if an association with
endometrial cancer had been reported but was not consistent across studies (or had not been
assessed in more than one study) at the time of SNP selection for this study.
We also examined the association of these genetic variants with circulating levels of sex
hormones and SHBG in healthy postmenopausal women, i.e. controls from this nested case-
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control study and a parallel case-control study of breast cancer nested within one of the three
cohorts [30].
Materials and Methods
Study Subjects
The case-control study was nested within three cohorts: the Northern Sweden Health and
Disease Study (NSHDS) in Umeå, Sweden [31], the New York University Women’s Health
Study (NYUWHS) in New York City, USA [32], and the ORDET cohort in Milan, Italy
[33]. The eligibility criteria, methods for data and biological sample collection and case
ascertainment in each cohort were described previously in a manuscript reporting on the
association of postmenopausal circulating levels of sex hormones and SHBG with risk of
endometrial cancer in this same nested case-control study [3]. Incident invasive endometrial
cancer cases (ICD-O codes 8010, 8140, 8210, 8260, 8310, 8323, 8380, 8382, 8441, 8460,
8461, 8480, 8481, 8560 and 8570) were included and two controls were individually-
matched to each case. Controls were selected at random among participants from the same
cohort who had not had a hysterectomy and were free of endometrial cancer at the time of
diagnosis of the case, and who matched the case on menopausal status at enrollment and age
(± 6 months) at, and date (± 3 months) of, blood donation.
Laboratory Methods
DNA extraction and genotyping—The NYUWHS started archiving blood clots and red
blood cell precipitates (that had been prepared at time of blood collection by centrifugation
of whole blood) about half-way through the recruitment period, resulting in such samples
being available as a source of DNA for 42% of the study participants. For the remainder of
the participants, DNA was extracted from serum. Samples were genotyped using TaqMan®
[34, 35] with an ABI 7900 Real-Time PCR instrument (Applied Biosystems, Foster City,
CA) and following the manufacturer’s instructions. The percent of successful genotyping
calls varied from 97 to 100%.
For the NSHDS and ORDET participants, DNA was isolated at the University of Umeå
from buffy coat material. Genotyping was performed at the SNP Technology Platform at
Uppsala University Hospital (www.genotyping.se) for seven SNPs. Five SNPs (rs4775936,
rs10046, rs1800440, rs6259, rs2234693) were assayed using the GenomeLab SNPStream
12plex-system (Beckman Coulter) and two (rs1056836 and rs1042838) the FP-TDI system.
UGT1A1 rs8175347 was assayed at the German Cancer Research Center in Heidelberg
using fluorescent fragment analysis on ABI PRISM 3100 Genetic analyzer (Applied
Biosystems) with the GeneMapper software version 3.0 (Applied Biosystems). The
percentage of samples with successful calls was 98% or greater for all SNPs except CYP19
rs10046 which had 92% of samples called.
For each genetic variant, pilot studies were conducted at each of the genotyping centers prior
to analyzing case-control samples. For the NYUWHS study, the pilot study included
different biological type samples obtained from the same women: serum/clot/cell precipitate
triplets from 50 women, serum/clot pairs from 34 women and serum/cell precipitate pairs
from 34 women, for a total of 284 samples. For the NSHDS and ORDET, duplicate samples
from 141 women (for a total of 282 samples) were included in the pilot study. Samples were
re-labeled to prevent the laboratory personnel from identifying samples contributed by the
same woman. The concordance between samples from the same participant was 99% or
greater for all genetic variants analyzed.
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Throughout all procedures, laboratory personnel were blinded as to the case/control status of
the samples. Samples of a case and her controls were always analyzed on the same plate.
Twelve quality control samples were included on each 96-well plate: 1 containing all
reagents except template DNA, 4 samples selected from the pilot study with known
genotype (1 homozygous wild-type, 1 homozygous variant and 2 heterozygotes) and 7
blinded duplicate samples. These quality control samples were interspersed at random on the
plate.
Sex hormone and SHBG assays—Sex hormones and SHBG had been measured for
women postmenopausal at blood donation who were included in a previous study of
circulating sex hormones and endometrial cancer based on the same 3 cohorts, resulting in
data available for 186 controls (84 from the NSHDS, 90 from the NYUWHS and 12 from
ORDET). To increase the sample size, we also included the postmenopausal controls (n =
410) from a parallel case-control study of breast cancer nested within the NYUWHS for
which the assays were done in the same laboratories during the same time period. Women
were classified as postmenopausal if they reported not having a menstrual period in the 6
months before blood donation or having had a bilateral oophorectomy (n=4 controls). A
total of 596 healthy women were included in these analyses, except for the two CYP1B1
SNPs which were genotyped only for the endometrial cancer case-control study. Assay
methods have been published previously [3, 30]. For the control women included in the
initial NYUWHS endometrial case-control study (n = 80), estradiol, estrone, testosterone
and androstenedione were measured using organic extraction and celite chromatography
with the appropriate fractions analyzed by radioimmuno-assays (RIA) at the Clinical Studies
Center of Quest Diagnostics Inc (Nichols Institute, San Juan Capistrano, CA). SHBG and
DHEAS were measured using an immunometric chemiluminescent assay on an IMMULITE
2000 instrument at NYU. For all other women (n = 516), sex hormones and SHBG assays
were carried out at the Hormone Laboratory at IARC, France. Estrone and androstenedione
were measured by double antibody RIA with reagents from Diagnostic System Laboratories
(Webster, TX), estradiol by ultrasensitive double antibody RIA with reagents from
Diagnostic System Laboratories, testosterone and DHEAS by RIA with reagents from
Immunotech (Marseille, France), and SHBG by immunoradiometric assay (IRMA) with
reagents from Cis-Bio (Gif-sur-Yvette, France). Inter-batch coefficients of variation were
≤15% for all assays. Free estradiol and free testosterone were calculated using mass action
equations and the concentrations of these two hormones and of SHBG, and assuming a
constant serum albumin concentration [36].
Statistical Methods
The chi-square test was used to assess deviation from the Hardy-Weinberg equilibrium. As
appropriate in studies with individual matching, the conditional logistic regression model
was used to calculate odds ratios for endometrial cancer according to genotype, and the
likelihood ratio test was used to assess statistical significance. Odds ratios are presented for
each genotype (no genetic model assumed), as well as per allele (assuming an additive
model), except for SNPs with less than 30 homozygous variant subjects (CYP1B1
rs1800440 (n = 27) and SHBG rs6259 (n = 15)) for which homozygous and heterozygous
subjects were grouped together. Simple models, adjusted for race only (and also controlling,
through matching, for menopausal status, age at blood donation, and duration of sample
storage), are presented as well as models adjusted for additional factors known to affect risk
of endometrial cancer, i.e. age at menarche, nulliparity, oral contraceptive use, hormone
replacement therapy use (containing estrogen and progestin or estrogen alone), and body
mass index (BMI). Heterogeneity of the genetic associations by cohort was tested by
comparing models with and without cross-product terms (cohort × genotype). Analyses
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limited to endometrioid cases (n= 321) and their matched controls, and to Caucasians (n=
362 cases and 645 controls), were also conducted.
To compare hormone and SHBG levels in postmenopausal women according to genotype,
geometric means and 95% confidence intervals were computed using general linear models.
Geometric means were adjusted for cohort, assay laboratory (to control for technical
variability between laboratories and assays), age (continuous), race (Caucasian, African-
American, Hispanic, Other/Unknown), and BMI (continuous). A trend test was performed to
assess whether the number of variant alleles (0, 1, or 2) was associated with hormone levels,
except for SNPs with small numbers of variant homozygous (CYP1B1 rs1800440and SHBG
rs6259) for which homozygous and heterozygous carriers were grouped.
Results
A total of 391 cases and 712 controls were included in the nested case-control study (216
cases and 386 controls from the NSHDS, 129 cases and 238 controls from the NYUWHS
and 46 cases and 88 controls from ORDET). Table 1 shows case and control subject
characteristics. As expected, cases tended to have younger age at menarche and older age at
menopause and to have higher weight and body mass index than controls. Also as expected,
the proportions of nulliparous, ever users of hormone replacement therapy and diabetics
were larger among cases than controls, while the proportion of ever oral contraceptive users
was lower.
For all SNPs the allelic frequencies were within the ranges observed in previous studies and
there was no evidence of deviation from the Hardy-Weinberg equilibrium in the control
groups of each cohort except for UGT1A1 rs8175347 (p = 0.02) in the NYUWHS, overall or
in analysis limited to the Caucasian controls. UGT1A1 rs8175347 frequencies were not
consistent with Hardy-Weinberg equilibrium among controls in the Shanghai Endometrial
Cancer Study [37] and the test for Hardy-Weinberg equilibrium was also marginally
significant (p=0.08) in one group of Caucasian controls from the Nurses’ Health Study [17].
Because of the high concordance between replicate samples observed in the pilot study and
quality control samples included in the case-control study, and because there was no
methodological evidence of genotyping errors, this polymorphism was retained in the
statistical analysis. Minor allele frequencies did not differ appreciably in Caucasians or
among women with endometrioid tumors.
Table 2 presents the odds ratios for endometrial cancer associated with the genetic
polymorphisms. Adjusting for known risk factors of endometrial cancer, the A allele of
rs4775936 in CYP19 was significantly associated with increased risk of endometrial cancer
(ORper allele = 1.22, 95% CI = 1.01–1.47, ptrend = 0.04), while the T allele of rs10046 was
marginally associated with risk (ORper allele = 1.20, 95% CI = 0.99–1.45, ptrend = 0.06). PGR
rs1042838 was also found to be marginally associated with risk (ORper allele = 1.25, 95% CI
= 0.96–1.61, ptrend = 0.09). No significant association with risk of endometrial cancer was
found for the other SNPs examined. Results of the analysis limited to Caucasians were very
similar to those of the overall analysis (data not shown). In analyses limited to the 321 sets
with endometrioid tumors, adjusted odds ratios were slightly lower for the CYP19 SNPs
(ORper allele = 1.19, 95% CI = 0.97–1.47, ptrend = 0.10 for rs4775936 and ORper allele = 1.16,
95% CI = 0.93 – 1.43, ptrend = 0.19 for rs10046), and higher for PGR rs1042838 (ORper allele
= 1.36, 95% CI = 1.01–1.82, ptrend = 0.04). None of the tests of interaction by cohort were
statistically significant.
Table 3 reports the geometric means of circulating estrogens and SHBG according to
genotype among healthy postmenopausal women. The two CYP1B1 polymorphisms (which
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were genotyped only in the 186 endometrial cancer study controls) were associated with
levels of estradiol and free estradiol: carrying the G allele of CYP1B1 rs1800440 was
associated with significantly lower levels of estradiol (p = 0.03) and free estradiol (p = 0.04),
while carrying the G variant of the CYP1B1 rs1056836 was associated with marginally
higher levels of estradiol (p = 0.07) and free estradiol (p = 0.07). For polymorphisms
genotyped in both the endometrial and breast cancer study controls (n=596), having 7 TA
repeats in UGT1A1 rs8175347 was associated with higher levels of estradiol (p = 0.05),
estrone (p = 0.05), and free estradiol (p = 0.03) as compared to carrying 6 repeats and the A
allele of SHBG rs6259 was associated with a higher level of SHBG (p = 0.05), as well as
estradiol (p = 0.03). Associations were in the same direction, although no longer statistically
significant, in analyses restricted to the controls for which hormones were measured in the
same laboratory and with the same assay method. None of the other polymorphisms were
associated with levels of estrogens or SHBG, and none of the polymorphisms were
associated with levels of testosterone, androstenedione, free testosterone or DHEAS (data
not shown).
Discussion
With the exception of one case-control study [6], our results for the two SNPs we examined
in CYP19 are consistent with the results of other studies. CYP19 rs4775936 (A allele) and
rs10046 (T allele), which are in linkage disequilibrium (r2 = 0.79 in our study), were found
to be associated with increased risk of endometrial cancer in two earlier studies [7, 38],
including a pooled analysis including 4998 cases and 8285 controls from 10 studies [38]
which found an association with rs749292, which is in in high linkage disequilibrium with
rs10046 (r2 > 0.83 [8]). Further, two pathway-based analyses support a role for CYP19
variants in endometrial cancer development [6, 39]. CYP19 codes for aromatase, the enzyme
responsible for the formation of estrogens from androgens. The A allele of rs4775936 and
the T allele of rs10046 have been shown to be associated with increased levels of estrogens
and/or of estrogen to androgen ratios in several studies [7–9, 40]. Although we did not
observe statistically significant differences in estrogen levels according to genotype in our
study, levels were in the expected directions, i.e. higher levels with the A allele of
rs4775936 and the T allele of rs10046.
It is well established that progesterone inhibits endometrial cell proliferation induced by
estrogens through binding to the progesterone receptor [41]. PGR rs1042838, the
polymorphism that we examined, is a non-synonymous SNP (V660L) in exon 4 which is in
complete linkage disequilibrium with the PROGINS allele, an Alu insertion in intron 7, and
with rs1042839, a silent SNP (H770H) in exon 5 [26]. The Alu insertion has been shown to
reduce transcript stability, and the amino acid substitution (V660L) to result in lower
efficiency in opposing proliferation of cells expressing the A isoform of the receptor [14],
the main isoform mediating the anti-proliferative effects of progesterone in the endometrium
[42]. The suggestive increase in risk we observed with PGR rs1042838 is consistent with
these observations, as well as with results of some [6, 16, 25], but not all [26, 43, 44], other
epidemiologic studies. The large study conducted by Lee et al., which examined 17
haplotype-tagging SNPs in the PGR gene, reported that the PROGINS allele, and haplotypes
containing the PROGINS allele, were associated with increased endometrial cancer risk
[25]. The PROGINS allele was also found to be associated with ovarian cancer of the
endometrioid type, which shares histological features with endometrial cancer [45]. PGR
rs1042838 was not associated with hormone levels in our study, which is in agreement with
the largest study to date (3852 women), which did not observe an association between
tagging polymorphisms in the PGR gene and estrogens, androgens, or SHBG [40].
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We observed that SHBG rs6259 carriers of allele A had higher circulating levels of SHBG
than non-carriers. Similar results were observed in several [9–11, 24, 46], although not all
[47, 48], prospective and cross-sectional studies of healthy women that examined this
association. This result is consistent with the observation that rs6259, a non-synonymous
SNP leading to the introduction of an N-glycosylation site, reduces the rate of clearance of
SHBG [49]. Higher levels of SHBG are associated with a reduced risk of endometrial cancer
which is thought to result primarily from its binding to estrogens, reducing their
bioavailability [3]. The observation of a 28% reduction in endometrial cancer risk in
postmenopausal women carrying the rs6259 variant in a large Chinese case-control study
was therefore in the expected direction [18]. However, a smaller Polish case-control study
reported an increased risk of endometrial cancer associated with the variant allele [6]. In our
study, SHBG rs6259 was not associated with risk, however, we had to group the
homozygous variant and recessive alleles since the allelic frequency of rs6259 is quite low
in Caucasians (10% in our study), as compared to Asians (~18%) [50], and thus may have
not been able to observe an association with the variant genotype. We also observed an
association of rs6259 allele A with higher levels of total estradiol. The only other study that
reported on the association of rs6259 with circulating estrogen, which was larger than ours
(1975 healthy postmenopausal women), found no difference in total estradiol according to
genotype [9], so it is possible that our finding is due to chance.
We did not find an association between risk of endometrial cancer and the UGT1A1
rs8175347, which is associated with a variable number of repeat TA in the A(TA)nTAA
sequence of the promoter. Although an early study [17] found that carriers of the *28 allele
(7 repeats) had a reduction in risk of endometrial cancer as compared to the wild type (*1, 6
repeats), several subsequent studies did not confirm this result [23, 37, 44, 51]. We found,
though, that controls carrying the *28 allele had significantly higher circulating levels of
estrogens than those carrying the *1 variant. A similar result was observed in another study,
although it did not reach statistical significance [12], while a third study reported higher
levels of estradiol in *28 homozygous carriers only; however this study had a small sample
size (n = 87) [52]. The findings that estrogens may be higher among carriers of the *28
allele, though, are consistent with the observation that the *28 allele may be associated with
reduced glucuronidation of various estrogens, including estradiol [12].
We did not observe an association of endometrial cancer risk with the two non-synonymous
CYP1B1 SNPs that we examined. Although some early studies found an increased risk with
the G (Ser) allele of rs1800440 [19] or the G (Val) allele of rs1056836 [20], subsequent
studies, including several larger studies, did not confirm these associations [6, 44, 51, 53–
56]. Although a meta-analysis of 12 case-control and nested case-control studies (n = 2059
cases and 3381 controls) reported a positive association for the G vs. C allele of rs1056836
and endometrial cancer risk (OR = 1.23, 95% CI = 1.06, 1.43, p=0.007), there was
significant heterogeneity across studies [57]. These two CYP1B1 SNPs were associated with
levels of circulating estradiol and free estradiol in our study: we observed lower levels of
estradiol with the G allele of rs1800440 and higher levels with the G allele of rs1056836. De
Vivo et al. also observed significant associations of these two SNPs with estradiol levels
[13]. However, whereas the association was in the same direction as in our study for
rs1056836, it was in the opposite direction for rs1800440. The largest two studies conducted
to date [1975 [9] and 2721 [40] women], as well as another smaller study [58], did not
observe any association between hormones and CYP1B1 SNPs . Although differences in
assay methodology or subject characteristics could contribute to these discrepancies, overall
these inconsistent results suggest that, if these SNPs do affect estrogen levels, the effect is
likely to be small.
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In conclusion, we observed associations of SNPs in the CYP19 and PGR genes with risk of
endometrial cancer. These associations are consistent with the well documented roles of
estrogens and progesterone in the development of endometrial cancer. Although the
associations between CYP19 and PGR SNPs and estrogen levels were not significant, they
were in the expected direction based on previous reports in the literature [7–9] and the
direction of their association with endometrial cancer risk (positive and inverse,
respectively). The lack of a significant association between these SNPs and estrogen levels
in our study may be due to several factors: 1) differences in the hormone assays used across
studies; 2) we only had a single hormone measurement and only one or two SNPs genotyped
in each gene, thus we may not have been able to capture more complex multi-SNP
associations with hormones or account for intra-individual variability in hormone levels over
time, and 3) associations between these genetic variants and endometrial cancer risk may not
be exclusively mediated through changes in circulating hormone levels. The risk of
endometrial cancer was not associated with the genetic variants we examined in the
CYP1B1, UGT1A1, SHBG and ESR1 genes. These results do not preclude a role of the
genes carrying these variants since we examined only one or two SNPs for each gene.
Although not associated with risk of endometrial cancer, some of the polymorphisms we
examined were associated with circulating levels of sex hormones and SHBG: SHBG
rs6259 was associated with levels of SHBG and estradiol, UGT1A1 rs8175347 with levels
of estradiol, free estradiol and estrone and CYP1B1 rs1800440 with levels of estradiol and
free estradiol. Similar observations were made in breast cancer studies where no association
with disease risk was found for genetic variants significantly related to estrogen levels,
despite the facts that estrogen levels are almost as strongly associated with breast cancer risk
than with endometrial cancer risk, and that these studies were much larger than the current
study [40, 59]. The impact of any single polymorphism on circulating hormone levels may
be too small to result in a significant association with endometrial cancer risk, in particular
in studies of moderate size.
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Table 1
Description of case and control subjects
Characteristic Cases (n = 391) Controls (n = 712) p-value
Age at blood donation, years, median (10th, 90th) 54.4 (44.0, 62.7) 54.5 (44.0, 63.0) Matched
Age at diagnosis, years, median (10th, 90th) 61.9 (51.6, 71.6)
Lag time between blood donation and diagnosis,
years, median (10th, 90th)
7.6 (1.8, 13.2)
Race, n (%) 0.26
  Caucasian 362 (96%) 645 (94%)
  Other 16 (4%) 44 (6%)
  Missing 13 23
Height, cm, median (10th, 90th) 162.8 (154.0, 170.0) 162.0 (154.0, 169.0) 0.41
Weight, kg, median (10th, 90th) 69.0 (54.0, 90.0) 64.0 (53.0, 82.0) <0.0001
Body mass index, kg/m2, n (%) <0.0001
  <25 143 (42%) 360 (57%)
  25-<30 105 (31%) 183 (29%)
  ≥30 92 (27%) 91 (14%)
Age at menarche, years, n (%) 0.01
  <12 73 (20%) 96 (14%)
  12 78 (21%) 125 (19%)
  13 97 (26%) 201 (30%)
  >13 121 (33%) 250 (37%)
  Missing 22 40
Postmenopausal at diagnosis, n (%) 192 (92%) 542 (95%) 0.19
  Missing 75 146
Age at menopause, years, n (%) 0.0002
  <50 55 (22%) 162 (34%)
  50–52 95 (37%) 158 (33%)
  >52 103 (41%) 154 (33%)
  Missing 138 238
Nulliparous, n (%) 83 (22%) 109 (16%) 0.02
  Missing 14 31
Ever used oral contraceptives, n (%) 108 (30%) 241 (36%) 0.04
  Missing 30 46
Ever used hormone replacement therapy, n (%) 155 (47%) 201 (33%) <0.0001
  Missing 64 102
Ever smoked, n (%) 146 (40%) 294 (43%) 0.38
  Missing 27 27
History of diabetes, n (%) 28 (8%) 25 (4%) 0.004
  Missing 50 62
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